SpiroSphere paired with ECG enables the consecutive collection of spirometry and ECG data during a single site visit. The platform consolidates all data into a single, unified database and streamlines the clinical trial process. It also eliminates the need for separate ECG devices or multiple databases for a study.
Philadelphia-based Clario originally launched SpiroSphere as a smart, lightweight pulmonary function testing (PFT) device. It initially did not include ECG functionality. However, introducing the wireless COR-12 ECG device enables customers to run integrated respiratory and cardiac safety trials on a single device and single database.
Clario SVP of Respiratory & Precision Motion, Tom Stuckey, called the device launch a “significant step in improving clinical trial technology.” Stuckey said the system optimizes data collection, efficiency and consistency to enhance respiratory trials with cardiac safety.
“Our SpiroSphere® wireless ECG focuses on the site and patient experience while maintaining the high-quality data collection standards as our wired ECG model,” said Ellen Street, EVP, Cardiac, Respiratory & Precision Motion at Clario. “With this wireless technology, site clinicians can now comfortably record both ECG and spirometry data in a single session on a single device, which can reduce the necessity for multiple devices, reduce burden, and accelerate trial timelines.”
